Communiqués Tempest Therapeutics, Inc.

Actions

TPST

US87978U2078

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 12/08/2026			Varia. 5j.	Varia. 1 janv.
1,210 ^USD	+2,54 %		+32,34 %	-57,84 %

22/07	Tempest Therapeutics, Inc. et Heibei Senlang Biotechnology Co., Ltd. concluent un accord de collaboration pour le développement de produits et des essais cliniques à l'initiative d'investigateurs	CI
15/07	Tempest Therapeutics dévoile son pipeline de thérapies CAR-T in vivo de nouvelle génération, avec une première étude clinique prévue pour le quatrième trimestre 2026	CI

Communiqués

21/07	Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T	AQ
15/07	Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026	AQ
04/06	Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors	AQ
29/05	Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds	AQ
14/05	Tempest Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
06/05	Tempest Presents Clinical Update at ISCT 2026 Annual Meeting	AQ
29/04	Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting	AQ
22/04	Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T	AQ
14/04	Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts	AQ
30/03	Tempest Reports Year End 2025 Financial Results and Provides Business Update	AQ
23/03	Tempest Therapeutics Announces Up To $6 Million Private Placement	AQ
11/03	Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026	AQ
25/02	Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026	AQ
11/02	Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets	AQ
04/02	Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets	AQ
20/01	Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders	AQ
26/11	Tempest Therapeutics : Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules	PU
25/11	Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules	AQ
19/11	Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027	AQ
05/11	Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update	AQ
11/08/25	Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update	AQ
30/06/25	Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China	AQ
11/06/25	Tempest Announces $4.6 Million Registered Direct Offering of Common Stock	AQ
05/06/25	Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC	AQ
13/05/25	Tempest Reports First Quarter 2025 Financial Results and Provides Business Update	AQ